GlassScriptPhysician profile
Anne C Goldberg
NPI 1093731317
$9,671.67
in general payments reported to CMS, 2019-2025
11 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $2,486 · 2021: $4,020 · 2022: $1,707 · 2023: $45.64 · 2024: $342 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $3,942.50 | 2020-2021 | |
| Akcea Therapeutics, INC. | $1,880.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,756.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $750.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $601.54 | 2019-2022 | |
| Amgen INC. | $395.85 | 2023-2025 | Repatha, Repatha |
| Kaneka Medical America LLC | $209.00 | 2020 | |
| Esperion Therapeutics, INC. | $136.55 | 2024 | Nexletol, Nexlizet |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.